Declining medical decision-making capacity in mild AD: a two-year longitudinal study

This is a report of a two‐year longitudinal study comparing healthy older adult subjects (n = 15) and mild Alzheimer's disease (AD) patients (n = 20) using an objective performance measure of medical decision‐making capacity (MDC). Capacity to consent to medical treatment was measured using the...

Full description

Saved in:
Bibliographic Details
Published inBehavioral sciences & the law Vol. 24; no. 4; pp. 453 - 463
Main Authors Huthwaite, Justin S., Martin, Roy C., Griffith, H. Randall, Anderson, Britt, Harrell, Lindy E., Marson, Daniel C.
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 01.07.2006
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN0735-3936
1099-0798
DOI10.1002/bsl.701

Cover

More Information
Summary:This is a report of a two‐year longitudinal study comparing healthy older adult subjects (n = 15) and mild Alzheimer's disease (AD) patients (n = 20) using an objective performance measure of medical decision‐making capacity (MDC). Capacity to consent to medical treatment was measured using the Capacity to Consent to Treatment Instrument (CCTI). The CCTI is a psychometric measure that tests MDC using a series of four core capacity standards: S1 (evidencing/communicating choice), S3 (appreciating consequences), S4 (providing rational reasons), and S5 (understanding treatment situation), and one experimental standard [S2] (making the reasonable treatment choice). For each standard, mild AD patients were assigned one of three capacity outcomes (capable, marginally capable, or incapable) based on cut‐off scores derived from control group performance. At baseline, mild AD patients performed equivalently with controls on simple standards of evidencing a choice (S1) and making the reasonable choice ([S2]), but significantly below controls on complex standards of appreciation, reasoning, and understanding (S3, S4, and S5) (p < 0.02). Control performance was stable over time on all capacity standards. At one‐year follow‐up, the mild AD group did not show significant decline from baseline on any capacity standard. However, at two‐year follow‐up the mild AD group showed significant declines from baseline on the three complex standards (S3, S4, and S5) (p < 0.02), and a trend on one of the simple standards (S1). Over the two‐year period, the proportion of marginally capable and incapable outcomes in the AD group increased substantially for four of the five standards (S1, S3, S4, and S5). Performance on [S2] remained stable over time in the AD group. We conclude that mild AD patients have impaired MDC at baseline, and demonstrate significant additional decline on complex consent abilities of appreciation, reasoning, and understanding over a two‐year period. AD patients also show emerging impairment on the simple consent ability of evidencing choice at two‐year follow‐up. Capacity outcome data reflect similar declines over time for these four consent standards. The findings suggest the value of early assessment and regular monitoring at two‐year intervals of MDC in patients with mild AD. Copyright © 2006 John Wiley & Sons, Ltd.
Bibliography:Alzheimer's Disease Research Center - No. NIH, NIA 1P50 AG16582
ArticleID:BSL701
Alzheimer's Disease Program Project - No. NIH, NIA 5 P01 AG06569-05
istex:B07799736F90212CFC9B4177C0A2FC8C62114226
This research was supported by an Alzheimer's Association Pilot Research Grant (PRG 91-122) (Marson, PI) and Investigator-Initiated Research Grant (IRG93-053), and by an Alzheimer's Disease Program Project grant (NIH, NIA 5 P01 AG06569-05) (Harrell, PI), an Alzheimer's Disease Research Center (NIH, NIA 1P50 AG16582) (Harrell, PI), and the Alzheimer's Disease Cooperative Study (NIH U01 AGO10483) (Thal, PI).
Alzheimer's Association - No. PRG 91-122; No. IRG93-053
Alzheimer's Disease Cooperative Study - No. NIH U01 AGO10483
ark:/67375/WNG-BBR0F0SC-S
This research was supported by an Alzheimer's Association Pilot Research Grant (PRG 91‐122) (Marson, PI) and Investigator‐Initiated Research Grant (IRG93‐053), and by an Alzheimer's Disease Program Project grant (NIH, NIA 5 P01 AG06569‐05) (Harrell, PI), an Alzheimer's Disease Research Center (NIH, NIA 1P50 AG16582) (Harrell, PI), and the Alzheimer's Disease Cooperative Study (NIH U01 AGO10483) (Thal, PI).
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:0735-3936
1099-0798
DOI:10.1002/bsl.701